Ask Warren

Optus Pharmaceutical

131030 · KOSDAQ · ₩131030 · 옵투스제약

₩5,890▼ ₩60 (1.01%)End-of-day · Oct 29, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩25B₩23B₩23B₩24B₩22B₩19B₩23B₩19B
Cost of sales₩10B₩9.5B₩11B₩11B₩9.9B₩7.7B₩10B₩8.7B
Gross profit₩14B₩14B₩12B₩13B₩12B₩11B₩13B₩11B
Operating income₩2.3B₩2.9B₩1.7B₩3.2B₩3.1B₩920M₩3B₩1.3B
Net income₩1.4B₩2.5B₩8.2B₩348M₩1.7B₩1.2B₩8.8B−₩904M
Net income to shareholders₩1.4B₩2.5B₩8.2B₩348M₩1.7B₩1.2B₩8.8B−₩904M

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩198B₩198B₩191B₩176B₩172B₩160B₩167B₩154B
Current assets₩68B₩69B₩67B₩59B₩75B₩70B₩78B₩85B
Cash and equivalents₩7B₩17B₩21B₩29B₩37B₩17B₩27B₩37B
Total liabilities₩18B₩22B₩26B₩25B₩25B₩15B₩23B₩15B
Current liabilities₩17B₩21B₩26B₩24B₩23B₩14B₩21B₩13B
Total equity₩180B₩176B₩165B₩150B₩147B₩145B₩144B₩139B
Shareholders' equity₩180B₩176B₩165B₩150B₩147B₩145B₩144B₩139B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations₩14B−₩5.2B₩5.4B₩5.3B₩7.9B−₩2.3B₩1.5B₩2.1B
Capital spending₩8.2B₩12B₩12B₩20B₩4.9B₩6.9B₩1.1B₩9.8B
Free cash flow₩6.1B−₩18B−₩7B−₩15B₩3B−₩9.2B₩387M−₩7.8B
Dividends paid——₩0₩0₩0₩0₩0₩0

Consolidated where available. Amounts in won.

Also known as: Optus Pharmaceutical / 옵투스제약 / 131030 / KRX:131030

Source: KRX statistical information